According to a new research, one in three people with severe skin illness were able to regrow hair after receiving a common arthritis medication.
The purpose of the phase 3 clinical trials is to use baricitinib, a Janus kinase inhibitor, to treat the alopecia areata, an often defiguring skin disease, which is distinguished by rapid scalp hair loss, and sometimes eyebrows and eyelashes.
Phase 3 clinical trials are the final testing hurdle before a new medication may be approved by the Food and Drug Administration (FDA).
Because the results show how effective baricitinib is, Dr.Brett King, an associate professor of dermatology at the Yale School of Medicine and lead author of the new study, published March 26 in the New England Journal of Medicine, is so exciting. These large, controlled trials tell us that we can alleviate some of the problems caused by this terrible disease.
Alopecia areata is an autoimmune disorder in which the body''s immune system attacks hair follicles. Each year, more than 200,000 new cases have arise in the United States. Although alopecia isata may develop in patients of any age, it typically occurs in people under the age of 40.
The condition is currently unknown as a result of the FDA''s approval.
For the first time, King and his colleagues conducted two large, random trials involving 1,200 people. The participants were adults with severe alopecia areata, who had lost at least half of their scalp hair; many had lost all of their scalp hair.
Participants were given a daily dose of either 4 milligrams of baricitinib, 2 milligrams of baricitinib, or a placebo for 36 weeks. One-third of the patients who received the larger dose had recovered hair.
According to researchers, baricitinib thwarts the disease by disrupting the communication of immune cells involved in harming hair follicles. It''s common to employ baricitinib and other JAK inhibitors to treat autoimmune forms of joint disease.
The Alopecia areata is a divisive journey, which is filled with chaos, confusion, and profound sadness for many who suffer from it, according to King. It will be incredible to have a medication to help individuals emerge on the other side, restore normality, and remember themselves and others who live there.
Researchers from the Kyorin University Faculty of Medicine, the Seoul National University College of Medicine, the Hebrew University of Jerusalem, Stanford University, the University of California-Irvine, the University of Minnesota, Eli Lilly and Company, and Sinclair Dermatology were co-authors.